European Equity pre-Market Summary - 25th September 2026: Futures firmer as energy retreats. M&A/Trade updates in focus.

Newsquawk StaffPublished On the live feed at , 20 minutes before this page
Newsquawk headlinesUTC

European Equity pre-Market Summary - 25th September 2026: Futures firmer as energy retreats. M&A/Trade updates in focus.

Additional European Equity News - 25th September 2026

German GfK Consumer Confidence (Oct) -30.6 vs. Exp. -27.4 (Prev. -26.8)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.

M&A/Trade

  • BP (BP/ LN): Considering a USD 2-5bln US shale deal; is evaluating acquisitions to expand its US shale business, according to sources; weighing a bid for Devon Energy's (DVN) Eagle Ford Asset, Reuters reports.
  • UBS (UBSG SW): Reportedly considering a merger with a foreign company as it looks to move out of Switzerland following a recent domestic Upper House capital ruling, Semafor reports.
  • ASML (ASML NA): Dutch PM Jetten said he has discussed preventing further US export restrictions on ASML with President Trump and lawmakers.
  • Auto Names: EU urges the UK to increase tariffs on Chinese cars to avoid ‘made in Europe’ barriers, according to FT.

Earnings

  • HelloFresh (HFG GY): Q2, Revenue beat, adj. EBITDA beat. Q3 revenue seen below the market view, FY outlook revised and shy of consensus. Underperformance in new customer acquisitions can be predominantly explained by the magnitude of the reduction in Q3 2026 marketing spend Y/Y.

Other

  • Airbus (AIR FP): Co. has reportedly identified a corrosion protection defect affecting more than 500 A321neos, including roughly 250 aircraft still in production. Not a safety risk.
  • AstraZeneca (AZN LN): Perioperative Imfinzi plus neoadjuvant enfortumab vedotin granted Priority Review in the US. Based on VOLGA Phase III trial results, which demonstrated statistically significant and clinically meaningful improvements in event-free survival and overall survival.
Context

A pre-market round-up of this kind is a positioning document rather than a single catalyst; the strands that historically carry through the session are the ones with named bidders and named targets, since sourced M&A reports tend to reprice the target's spread against its peer set and hold, while speculative strategic reviews fade unless confirmed. On the BP and Devon angle, large integrateds buying back into US shale has precedent, and the usual sequence is an initial pop in the target, a modest derating of the acquirer on funding questions, then a wait for either denial or filing. The UBS strand is the more structurally interesting one: a domestically constrained bank contemplating a foreign combination after an adverse capital ruling fits a pattern where regulatory pressure, not strategic logic, drives the conversation, and such reports have tended to draw swift official and political pushback that caps the move. The ASML export-restriction diplomacy and the EU tariff noise on Chinese autos are headline-sensitive and have historically traded in whipsaw fashion, reversing on the next official utterance. The Airbus defect disclosure, explicitly flagged as not a safety issue, belongs to the category of production-cost stories that weigh on the stock for a session or two unless delivery schedules are confirmed hit. The tells for the session are confirmation or denial on the two M&A reports and any official response out of Bern.

Related headlines

The whole workspace, free to try.

Try it free